Suggested remit - To appraise the clinical and cost effectiveness of lumacaftor in combination with ivacaftor within its marketing authorisation for treating cystic fibrosis in children ages 2 to 11 years old who are homozygous for the F508del mutation
This appraisal was due to start at the end of September. However the company, Vertex Pharmaceuticals, has informed us that it will not be participating in the appraisal. As a consequence, we have now suspended this appraisal. Please monitor this webpage for further updates.
 
Status Suspended
Process STA 2018
ID number 1486

Project Team

Project lead Kate Moore

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 October 2019 Suspended, This appraisal was due to start at the end of September. However the company, Vertex Pharmaceuticals, has informed us that it will not be participating in the appraisal. As a consequence, we have now suspended this appraisal. Please monitor this webpage for further updates.
22 August 2019 Draft scope documents
25 September 2018 - 23 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance